Natalia Saldaña-García

Dr. Natalia Saldaña-García


Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
11 March 2024 in Cytotherapy
Verified
Journal Article
Open access
MMMaría Jesús del Cerro Marín
María Jesús del Cerro Marín
IOItziar Garcia Ormazábal
Itziar Garcia Ormazábal
AGAna Gimeno-Navarro
Ana Gimeno-Navarro
MÁMaría Álvarez-Fuente
María Álvarez-Fuente
PLPaloma López-Ortego
Paloma López-Ortego
MTMáximo Vento Torres
Máximo Vento Torres
Currently, there is a lack of effective treatments or preventive strategies for bronchopulmonary dysplasia (BPD). Pre-clinical studies with mesenchymal stromal cells (MSCs) have yielded encouraging results. The safety of administering repeated intravenous doses of umbilical cord tissue-derived mesenchymal stromal cells (UC-MSCs) has not yet been tested in extremely-low-gestational-age newborns (ELGANs). to test the safety and feasibility of administering three sequential intravenous doses of UC-MSCs every 7 days to ELGANs at risk of developing BPD. In this phase 1 clinical trial, we recruited ELGANs (birth weight ≤1250 g and ≤28 weeks in gestational age [GA]) who were on invasive mechanical ventilation (IMV) with FiO2 ≥ 0.3 at postnatal days 7-14. Three doses of 5 × 106/kg of UC-MSCs were intravenously administered at weekly intervals. Adverse effects and prematurity-related morbidities were recorded. From April 2019 to July 2020, 10 patients were recruited with a mean GA of 25.2 ± 0.8 weeks and a mean birth weight of 659.8 ± 153.8 g. All patients received three intravenous UC-MSC doses. The first dose was administered at a mean of 16.6 ± 2.9 postnatal days. All patients were diagnosed with BPD. All patients were discharged from the hospital. No deaths or any serious adverse events related to the infusion of UC-MSCs were observed during administration, hospital stays or at 2-year follow-up. The administration of repeated intravenous infusion of UC-MSCs in ELGANs at a high risk of developing BPD was feasible and safe in the short- and mid-term follow-up.

30 July 2025 in Biomedicines
Verified
Journal Article
Open access
PDF file
GGGema Gomez-Casado
Gema Gomez-Casado
NSNatalia Saldaña-García
Natalia Saldaña-García
Ernesto González-MesaErnesto González-Mesa
Ernesto González-Mesa
AOAlmudena Ortega-Gomez
Almudena Ortega-Gomez
Obesity is a multifactorial condition that influences metabolic, endocrine, inflammatory, circadian, and behavioral systems. These disruptions can adversely affect the initiation of lactogenesis II—the critical process marking the onset of copious milk secretion following childbirth. In mothers with obesity, prolonged inflammation within the mammary gland, a blunted hormonal response (notably of prolactin), altered progesterone and estrogen dynamics, high leptin levels, and misaligned circadian rhythms contribute significantly to delayed lactogenesis. In addition, mechanical difficulties and psychological factors further hinder effective breastfeeding. This report synthesizes evidence from human epidemiological studies and animal models that elucidate the diverse mechanisms linking maternal obesity to delayed lactogenesis. We review the role of obesity-associated inflammatory mediators in impairing mammary tissue remodeling, the endocrine aberrations that impair lactogenic signaling, the consequences of circadian disruption on hormonal rhythmicity, and the behavioral influences that challenge effective breastfeeding. Finally, we discuss the clinical implications of these findings and propose future research directions targeting endocrine modulation, anti-inflammatory therapy, circadian interventions, and enhanced lactation support strategies for mothers with obesity.

24 February 2022 in Journal of Clinical Medicine
Verified
Journal Article
Open access
PDF file
NSNatalia Saldaña-García
Natalia Saldaña-García
MEMaría Gracia Espinosa-Fernández
María Gracia Espinosa-Fernández
JMJose David Martínez-Pajares
Jose David Martínez-Pajares
ETElías Tapia-Moreno
Elías Tapia-Moreno
MMMaría Moreno-Samos
María Moreno-Samos
TSTomás Sánchez-Tamayo
Tomás Sánchez-Tamayo
Background: Benefits of antenatal corticosteroids have been established for preterm infants who have received the full course. In imminent preterm labours there is no time to administer the second dose 24 h later. Objective: To determine whether the administration of two doses of betamethasone in a 12 h interval is equivalent to the effects of a full maturation. Methods: We performed a retrospective cohort study including preterm infants ≤34 weeks gestational age at birth and ≤1500 g, admitted to an NICU IIIC level in a tertiary hospital from 2015 to 2020. The population was divided into two cohorts: complete maturation (CM) (two doses of betamethasone 24 h apart), or advanced maturation (AM) (two doses of betamethasone 12 h apart). The primary outcomes were mortality or survival with severe morbidities. The presence of respiratory distress syndrome and other morbidities of prematurity were determined. These variables were analysed in the neonates under 28 weeks gestational age cohort. Neurodevelopment at 2 years was evaluated with the validated Ages and Stages Questionnaires®, Third Edition (ASQ®-3). Multiple regression analyses were performed and adjusted for confounding factors. Results: A total of 275 preterm neonates were included. Serious outcomes did not show differences between cohorts, no increased incidence of morbidity was found in AM. A lower percentage of hypotension during the first week (p = 0.04), a tendency towards lower maximum FiO2 (p = 0.14) and to a shorter mechanical ventilation time (p = 0.14) were observed for the AM cohort. Similar results were found in the subgroup of neonates under 28 weeks gestational age. There were no differences in cerebral palsy or sensory deficits at 24 months of corrected age, although the AM cohort showed a trend towards better scores on the ASQ3 scale. Conclusions: Administration of betamethasone every 12 h showed similar results to the traditional pattern with respect to mortality and severe morbidities. No deleterious neurodevelopmental effects were found at 24 months of corrected age. Earlier administration of betamethasone at 12 h after the first dose would be an alternative in imminent preterm delivery. Further studies are needed to confirm these results.

21 December 2021 in Journal of Clinical Medicine
Verified
Journal Article
Open access
PDF file
NSNatalia Saldaña-García
Natalia Saldaña-García
MEMaría Gracia Espinosa-Fernández
María Gracia Espinosa-Fernández
CGCelia Gómez-Robles
Celia Gómez-Robles
APAntonio Javier Postigo-Jiménez
Antonio Javier Postigo-Jiménez
NBNicholas Bello
Nicholas Bello
TSTomás Sánchez-Tamayo
Tomás Sánchez-Tamayo
Background: A complete course of prenatal corticosteroids reduces the possibility of morbimortality and neonatal respiratory distress syndrome (RDS). Occasionally, it is not possible to initiate or complete the maturation regimen, and the preterm neonate is born in a non-tertiary hospital. This study aimed to assess the effects of a single dose of betamethasone within 3 h before delivery on serious outcomes (mortality and serious sequelae) and RDS in preterm neonates born in tertiary vs. non-tertiary hospitals. Materials and methods: Preterm neonates who were <35 weeks and ≤1500 g, treated during a period of five years in a level IIIC NICU, were included in this retrospective cohort study. Participants were divided into groups as follows: NM, non-matured; PM, partial maturation (one dose of betamethasone up to 3 h antepartum). They were further divided based on their place of birth (NICU-IIIC vs. non-tertiary hospitals). The morbimortality rates and the severity of neonatal RDS were evaluated. Results: A total of 76 preterm neonates were included. A decrease in serious outcomes was found in the PM group in comparison to the NM group (OR = 0.2; 95%CI (0.07–0.9)), as well as reduced need for mechanical ventilation (54% vs. 68%). The mean time between maternal admission and birth was similar in both cohorts. The mean time from the administration of betamethasone to delivery was 1 h in the PM cohort. With regard to births in NICU-IIIC, the PM group performed better in terms of serious outcomes (32% vs. 45%) and the duration of mechanical ventilation (117.75 vs. 132.18 h) compared to the NM group. In neonates born in non-tertiary hospitals with PM in comparison to the NM group, a trend towards a reduced serious outcome (28.5% vs. 62.2%) and a decreased need for mechanical ventilation (OR = 0.09; 95%CI (0.01–0.8)) and maximum FiO2 (p = 0.01) was observed. Conclusions: A single dose of betamethasone up to 3 h antepartum may reduce the rate of serious outcomes and the severity of neonatal RDS, especially in non-tertiary hospitals.

11 April 2023 in Andes Pediatrica
Verified
Journal Article
Open access
PDF file
NSNatalia Saldaña-García
Natalia Saldaña-García
JMJosé David Martínez-Pajares
José David Martínez-Pajares
MPMercedes Chaffanel Peláez
Mercedes Chaffanel Peláez
MSMa. del Mar Serrano-Martín
Ma. del Mar Serrano-Martín
MEMa. de Gracia Espinosa-Fernández
Ma. de Gracia Espinosa-Fernández
TSTomás Sánchez-Tamayo
Tomás Sánchez-Tamayo
Los corticoides prenatales disminuyen la mortalidad y el distrés respiratorio (SDR) en recién nacidos prematuros (RNPT). Estos beneficios decrecen tras la semana de su administración, recomendándose un rescate si existe una nueva amenaza de parto prematuro. La repetición de corticoides prenatales puede tener efectos deletéreos y sus beneficios son controvertidos en el retraso del crecimiento intra- uterino (RCIU). Objetivo: comprobar los efectos del rescate con betametasona prenatal en la morbimortalidad neonatal, el SDR y el neurodesarrollo a los 2 años en prematuros con RCIU. Pacientes y Método: Estudio retrospectivo de RNPT ≤ 34 semanas y ≤ 1.500 g divididos en cohortes según la exposición a betametasona prenatal: Ciclo-único (2 dosis) vs Rescate (3 dosis). Se realizan subgrupos para ≥ 30 semanas. Se realizó un seguimiento de ambas cohortes hasta los 24 meses de edad corregida. Se aplicó el cuestionario Ages & Stages Questionnaire (ASQ)® para evaluar el neurodesarrollo. Resultados: Se incluyen 62 RNPT. El grupo Rescate vs. Ciclo-único no muestra diferencias en morbimortalidad y sí menor intubación (p = 0,02), sin diferencias en el soporte respiratorio a los 7 días de vida. RNPT ≥ 30 semanas con Rescate presentan mayor morbimortalidad (p = 0,03) y displasia broncopulmonar (DBP) (p = 0,02), sin diferencias en el SDR. El grupo rescate muestra peores puntuaciones medias en la escala ASQ-3, sin diferencias significativas en parálisis cerebral o déficits sensoriales. Conclusiones: El rescate no disminuye la morbimortalidad y sí reduce la intubación al nacimiento. Sin embargo, en ≥ 30 semanas no se observa este beneficio y la población expuesta a rescate presenta más DBP y menores puntuaciones en la escala ASQ-3 a los 2 años. Futuros estudios deben ir encaminados a la individualización de la terapia con corticoides prenatales.